Aquestive Therapeutics In... (AQST)
NASDAQ: AQST
· Real-Time Price · USD
3.01
0.08 (2.91%)
At close: May 01, 2025, 3:59 PM
3.05
1.30%
After-hours: May 01, 2025, 05:37 PM EDT
Aquestive Therapeutics Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Co-Development and Research Fees Revenue | 492K | 403K | 335K | 490K | 124K | 453K | 254K | 395K | 241K | 403K | 218K | 523K | 456K | 2.36M | 394K | 328K | 12.93M | 426K | 1.18M | 1.36M | 424K | 4.62M | 1.21M | 907K | 712K |
| Co-Development and Research Fees Revenue Growth | +22.08% | +20.30% | -31.63% | +295.16% | -72.63% | +78.35% | -35.70% | +63.90% | -40.20% | +84.86% | -58.32% | +14.69% | -80.69% | +499.24% | +20.12% | -97.46% | +2934.74% | -63.90% | -12.98% | +219.81% | -90.83% | +280.72% | +33.85% | +27.39% | n/a |
| License and Royalty Revenue Revenue | 2.16M | 1.13M | 1.87M | 1.1M | 1.48M | 919K | 917K | 376K | 552K | 506K | 380K | 328K | 10.66M | 6.51M | 373K | 5.9M | 7.26M | 6.92M | 557K | 9.15M | 8.91M | 6.67M | 7.31M | 3.35M | 8.68M |
| License and Royalty Revenue Revenue Growth | +90.99% | -39.56% | +69.81% | -25.52% | +61.15% | +0.22% | +143.88% | -31.88% | +9.09% | +33.16% | +15.85% | -96.92% | +63.80% | +1645.58% | -93.68% | -18.68% | +4.96% | +1141.65% | -93.92% | +2.69% | +33.68% | -8.79% | +117.94% | -61.37% | n/a |
| Manufacture and Supply Revenue Revenue | 10.67M | 10.52M | 11M | 11.41M | 11.64M | 9.76M | 8.92M | 8.41M | 9.87M | 9.17M | 7.69M | 10.45M | n/a | n/a | 4.8M | n/a | n/a | n/a | 14M | n/a | n/a | n/a | 8.07M | 9.01M | n/a |
| Manufacture and Supply Revenue Revenue Growth | +1.45% | -4.36% | -3.60% | -1.95% | +19.20% | +9.41% | +6.08% | -14.82% | +7.67% | +19.27% | -26.40% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -10.38% | n/a | n/a |
| Manufactured Product, Other Revenue | 217K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Manufactured Product, Other Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|
| Non-Us Revenue | 13.48M | 7.76M | 7.97M | 4.89M | 4.32M |
| Non-Us Revenue Growth | +73.72% | -2.67% | +62.93% | +13.37% | n/a |
| United States Revenue | 37.1M | 39.92M | 42.86M | n/a | n/a |
| United States Revenue Growth | -7.06% | -6.86% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 12.13M | 11.36M | 10.69M | 9.55M | 7.38M | 7.36M | 7.46M | 11.81M | 12.46M | 15.59M | 13.02M | 14.98M | 12.13M | 13.13M | 13.23M | 15.58M | 11.8M | 13.89M | 14.61M | 16.47M | 13.71M | 16.25M | 17.91M | 18.7M | 12.35M | 33.65M | 7.57M | 7.57M | 6.16M | 5.22M | 6.13M |
| Selling, General, and Administrative Revenue Growth | +6.78% | +6.24% | +11.93% | +29.32% | +0.34% | -1.27% | -36.89% | -5.19% | -20.07% | +19.71% | -13.08% | +23.51% | -7.65% | -0.73% | -15.09% | +32.02% | -15.05% | -4.92% | -11.30% | +20.13% | -15.59% | -9.28% | -4.25% | +51.50% | -63.31% | +344.54% | +0.05% | +22.79% | +17.96% | -14.77% | n/a |
| Research and Development Revenue | 5.27M | 4.16M | 5.93M | 2.89M | 3.2M | 3.47M | 3.55M | 4.28M | 3.23M | 5.2M | 4.77M | 4.4M | 4.73M | 4.26M | 3.66M | 4.42M | 7.26M | 3.85M | 4.35M | 3.06M | 5.06M | 8.15M | 4.3M | 5.68M | 4.53M | 7.99M | 4.9M | 6.27M | 5.68M | 4.84M | 5.34M |
| Research and Development Revenue Growth | +26.60% | -29.84% | +105.40% | -9.64% | -7.98% | -2.09% | -17.09% | +32.36% | -37.82% | +8.90% | +8.48% | -6.90% | +10.89% | +16.48% | -17.31% | -39.05% | +88.72% | -11.64% | +42.43% | -39.62% | -37.88% | +89.43% | -24.28% | +25.34% | -43.28% | +63.11% | -21.85% | +10.33% | +17.51% | -9.47% | n/a |